![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
T. Rowe Price Health Sciences Fund Inc. (MM) | NASDAQ:PRHSX | NASDAQ | Fund |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
The healthcare sector is one of the most desirable avenues for parking investments when markets are headed south. The demand for such services usually remains unchanged even during an economic downturn and investments in the sector provide sufficient protection to the capital invested. Several pharmaceutical companies also provide regular dividends, which can help mitigate losses from falling share prices. Healthcare mutual funds provide the perfect avenue for investors looking to invest in this sector.
Below we will share with you the 5 best performing healthcare mutual funds year to date. To view the Zacks Rank and past performance of all healthcare funds, investors can click here to see the complete list of funds.
Mutual Fund |
Zacks Rank |
Total Return YTD |
ProFunds Biotech Ultra Sector |
#2 Buy |
31.0% |
Rydex Biotechnology |
#3 Hold |
23.3% |
T. Rowe Price Health Sciences |
#3 Hold |
19.8% |
Fidelity Select Biotechnology |
#4 Sell |
19.6% |
Franklin Biotechnology Discovery A |
#3 Hold |
18.4% |
The healthcare mutual fund has an expense ratio of 2.87% compared to a category average of 1.51%.
Rydex Biotechnology (RYOIX) seeks capital growth. The fund invests a large share of its assets in equity securities and derivatives issued by domestic biotechnology companies. The fund is non-diversified and seeks long-term capital growth. The healthcare mutual fund returned 16.49% over the last one year period.
Michael P. Byrum is the fund manager and has managed this healthcare mutual fund since 1998/.
T. Rowe Price Health Sciences (PRHSX) invests the majority of its assets in common stocks of companies whose primary operations are related to healthcare products medicine or life sciences. The fund focuses on investing in large and mid-cap firms but may also purchase stock of smaller companies. The healthcare mutual fund returned 12.18% over the last one year period.
The healthcare mutual fund has a minimum initial investment of $2,500 and an expense ratio of 0.82% compared to a category average of 1.57%.
Fidelity Select Biotechnology (FBIOX) seeks appreciation of capital. The fund invests a large share of its assets in companies seeking to benefit from advances in the biotechnological sector. It focuses on acquiring common stocks and may also purchases securities issued by foreign companies. The healthcare mutual fund returned 19.57% over the last one year period.
As of April 2012, this healthcare mutual fund held 149 issues, with 11.41% of its total assets invested in Gilead Sciences Inc.
Franklin Biotechnology Discovery A (FBDIX) seeks capital growth. The fund invests the majority of its assets in securities issued by biotechnology and drug discovery companies. The fund primarily purchases equity securities, focusing on common stock. Not more than 20% of its assets may be invested in securities from other sectors. The healthcare mutual fund returned 13.18% over the last one year period.
Evan S. McCulloch is the fund manager and has managed this healthcare mutual fund since 1997
To view the Zacks Rank and past performance of all healthcare mutual funds, investors can click here to see the complete list of funds.
About Zacks Mutual Fund Rank
By applying the Zacks Rank to mutual funds, investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward. Learn more about the Zacks Mutual Fund Rank at http://www.zacks.com/funds
1 Year T. Rowe Price Health Sciences Fund Inc. (MM) Chart |
1 Month T. Rowe Price Health Sciences Fund Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions